Data Sheet (Cat.No.T15056)

DB07107

Chemical Properties



CAS No. : 552332-71-5

Formula: C23H22N4O

Molecular Weight: 370.45

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).
Targets(IC50)	Akt,Bcr-Abl
In vitro	DB07107 from DrugBank showed the highest binding energy (XP: -14.045 kcal/mol). DB07107 is more potent in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6994 mL	13.4971 mL	26.9942 mL
5 mM	0.5399 mL	2.6994 mL	5.3988 mL
10 mM	0.2699 mL	1.3497 mL	2.6994 mL
50 mM	0.054 mL	0.2699 mL	0.5399 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Banavath HN, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014 Nov 10;4:6948.
Li Q, et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett. 2006 Mar 15;16 (6):1679-85.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481